Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Growth Analysis, By Type(Pirfenidone and nintedanib), By Distribution channel(Hospital pharmacies, retail pharmacies and online providers), By Region - Industry Forecast 2024-2031

Idiopathic Pulmonary Fibrosis Treatment Market size was valued at USD 16.13 billion in 2022 and is poised to grow from USD 17.12 billion in 2023 to USD 27.55 billion by 2031, at a CAGR of 6.13% during the forecast period (2024-2031). 

The global idiopathic pulmonary fibrosis treatment market has experienced significant growth in recent years. The primary reason behind the market growth is growing population, and rising awareness of diseases. Idiopathic pulmonary fibrosis(IPF) is the most common type of pulmonary fibrosis. It’s a disease that causes scarring of the lungs. Scarring causes difficulty in the lungs and makes it difficult to breathe. The landscape of treatment for idiopathic pulmonary fibrosis includes pharmacological interventions, such as Nintedanib and Pirfenidone, which are approved by regulatory bodies for showing progress in disease. In addition, lung transplantation is considered as a viable treatment option for eligible patients in the end stage of this pulmonary fibrosis. During past years, there has been a surge in R&D activities that lead to the emergence of potential therapeutic targets and promising drug entrants. Moreover, the market is also experiencing growth by key market player’s expertise.  Collaborations and partnerships between research institutes and pharmaceutical companies to accelerate the development of effective treatment options.